Dividends, Upcoming Conference Schedules, Quarterly Earnings Releases, and Acquisitions - Research Reports on Wells Fargo, JPMorgan, Citigroup, Regions and Pfizer

NEW YORK, July 31, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Wells Fargo & Co. (NYSE: WFC), JPMorgan Chase & Co. (NYSE: JPM), Citigroup Inc. (NYSE: C), Regions Financial Corp. (NYSE: RF) and Pfizer Inc. (NYSE: PFE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5304-100free.

--
Wells Fargo & Co. Research Reports
On July 22, 2014, Wells Fargo & Co. (Wells Fargo) announced that the Company has declared a quarterly common stock dividend of $0.35 per share, payable on September 1, 2014, to holders of record on August 8, 2014. The dividend was approved by the Company's Board of Directors. Further, the recently announced dividend is unchanged from dividend announced in the preceding quarter. The full research reports on Wells Fargo are available to download free of charge at:

http://www.analystsreview.com/Jul-31-2014/WFC/report.pdf

--
JPMorgan Chase & Co. Research Reports
On July 28, 2014, JPMorgan Chase & Co. (JPMorgan) reported that the Company's CFO Marianne Lake will present at the upcoming Barclays Global Financial Services Conference on September 9, 2014 at 1:00 p.m. ET at the Hilton Midtown in New York. The Company added that a live audio webcast of the presentation will be available on the day of the conference at its website. The full research reports on JPMorgan are available to download free of charge at:

http://www.analystsreview.com/Jul-31-2014/JPM/report.pdf

--
Citigroup Inc. Research Reports
On July 16, 2014, Citigroup Inc. (Citigroup) announced that the Company's Board of Directors has declared a quarterly dividend of $0.01 per share on its common stock, payable on August 22, 2014 to holders of record on August 4, 2014. The Company's recently announced dividend is unchanged from the dividend announced in the previous quarter. The full research reports on Citigroup are available to download free of charge at:

http://www.analystsreview.com/Jul-31-2014/C/report.pdf

--
Regions Financial Corp. Research Reports
On July 22, 2014, Regions Financial Corp. (Regions) released its Q2 2014 financial results with total revenue of $1.3 billion, down 2.0% YoY. The Company's Q2 2014 net interest margin (NIM) from continuing operations came in at 3.24%, compared to 3.16% in Q2 2013. During the quarter, the Company's Tier 1 Capital ratio was 12.5%, while Basel III common equity Tier 1 ratio (non-GAAP) was 11.0%, reflecting a strong capital position. The Company's Q2 2014 net income available to common shareholders increased to $292 million or $0.21 per diluted share, from $259 million or $0.18 per diluted share in Q2 2013. Commenting on the results, Grayson Hall, Chairman, President and CEO, stated, "These results demonstrate continued momentum as we effectively execute our business plans. By focusing on meeting our customers' needs, we are delivering sustainable and diversified revenue growth while controlling expenses and maintaining prudent credit standards." The full research reports on Regions are available to download free of charge at:

http://www.analystsreview.com/Jul-31-2014/RF/report.pdf

--
Pfizer Inc. Research Reports
On July 16, 2014, Pfizer Inc. (Pfizer) and InnoPharma Inc. (InnoPharma) jointly announced an agreement under which Pfizer will acquire InnoPharma for an upfront cash payment of $225 million, along with contingent milestone payments of up to $135 million. The Company informed that InnoPharma's current portfolio includes 10 generic products approved by the U.S. Food and Drug Administration (FDA) plus a pipeline of 19 products filed with FDA and more than 30 injectable and ophthalmic products under development. John Young, Group President, Pfizer Global Established Pharma (GEP), said, "Today's announcement is an important milestone as we continue to look for innovative growth opportunities for our sterile injectables portfolio, which will increase to seventy three products with this acquisition." The Company expects the transaction to close in Q3 2014, subject to U.S. regulatory approvals. The full research reports on Pfizer are available to download free of charge at:

http://www.analystsreview.com/Jul-31-2014/PFE/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED